Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (KL2TR001856)
National Institute of Allergy and Infectious Diseases (R01AI165671, R01AI104895)
- License Information
-
More Information
Article History
Accepted: 22 September 2024
First Online: 28 November 2024
Declarations
:
: This work was supported in whole or in part with federal funds from the National Institutes of Health: KL2 TR001856 (AI), R01 AI104895 (YD), and R01 AI165671 (VGF).
: AI declares no relevant conflicts of interest. VGF reports the following: Grants/research support: Astra Zeneca; MedImmune; Merck; ContraFect, Karius, Genentech, Regeneron, Basilea. Paid Consultant: Astra Zeneca; GSK; Armata, Debiopharm; Genentech; Basilea, Affinergy, Janssen, ContraFect, Destiny. Royalties: UptoDate. Stock Options: ArcBio, Valanbuio. Patent pending: sepsis diagnostics. YD reports the following: Paid Consultant: Gilead Sciences; Moderna; GSK; Pfizer; AbbVie; Shionogi; Meiji Seika Pharma.
: AI conceived the idea for the article, performed the literature search and drafted the manuscript. VGF and YD critically revised the work.
: Ethics approval, informed consent and data availability are not applicable for this review.
